VivoSeq
Nephrology

Diabetic Nephropathy

109

Pipeline Programs↗

10

Active Trials↗

47

Companies Involved↗

Diabetic Nephropathy is a highly competitive landscape with 109 programs across 47 companies. The most active players are Tibotec Pharmaceuticals, Ireland, Asia Cell Therapeutics (Shanghai) Co., Ltd., Tanabe Pharma Corporation. 31 therapies are approved with 26 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

19/100

Mech. Concentration

10/100

Completion Rate

87/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland

1 program

Phase 1A

Asia Cell Therapeutics (Shanghai) Co., Ltd.

1 program

Phase 1Tanabe Pharma Corporation logo

Tanabe Pharma Corporation

1 program

Phase 2C

Concert Pharmaceuticals

1 program

Phase 2K

Korea Otsuka Pharmaceutical Co., Ltd.

1 program

Phase 2D

Dong Wha Pharmaceutical Co. Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

120 of 129 classified programs — the dominant modality here.

7%ALL OTHERSPeptide54%Cell therapy43%

Small molecule leads; the ring shows all 129 classified programs, each share of the total. Modality classified for 99% of 133 pipeline programs.

Analysis

Trial Status

124

clinical trials

Completed79 · 64%
Unknown status23 · 19%
Terminated11 · 9%
Not yet recruiting5 · 4%
Recruiting3 · 2%
Active, not recruiting2 · 2%
Other1 · 1%

Clinical Trials

Trial Activity

124 trials

Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Recruiting·—·Phase 2/3·NCT06441591·64 enrolled
Transformative Research in Diabetic Nephropathy 2.0
Recruiting·UUniversity of Pennsylvania·N/A·NCT07444203·200 enrolled
Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial
Recruiting·PPT. Prodia Stem Cell Indonesia·Phase 1/2·NCT07396155·10 enrolled
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
Active, not recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT06532682·54 enrolled
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
Active, not recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00342927·9,084 enrolled
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT06068439·355 enrolled
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Not yet recruiting·—·N/A·NCT06668753·114 enrolled
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients
Not yet recruiting·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·Phase 3·NCT06606093·348 enrolled
Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diabetic Nephropathy Driven by Multi-Omics and Artificial Intelligence
Not yet recruiting·—·N/A·NCT07459946·198 enrolled
Evidence-Based Evaluation of Naoxintong Capsule in the Treatment of Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Not yet recruiting·—·Approved·NCT07698223·410 enrolled
Renoprotection in Early Diabetic Nephropathy in Pima Indians
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00340678·170 enrolled
Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
Completed·YYokohama City University Medical Center·Phase 4·NCT00295555·98 enrolled
Effects of PH3 in Diabetic Nephropathy
Completed·PPhytoHealth Corporation·Phase 2·NCT01068041·100 enrolled
(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
Completed·Roche logoRoche·Phase 3·NCT00354341·170 enrolled
A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy
Completed·Otsuka logoOtsuka·Phase 4·NCT01252056·353 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)